APEN - Apollo Endosurgery, Inc.
| Previous Close | 3.5100 |
| Open | 3.4800 |
| Bid | 3.05 x 1400 |
| Ask | 5.60 x 900 |
| Day's Range | 3.5100 - 3.6200 |
| 52 Week Range | 3.0200 - 9.6500 |
| Volume | 9,280 |
| Avg. Volume | 47,555 |
| Market Cap | 77.065M |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.86 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
- Simply Wall St.•3 days ago
Does Market Volatility Impact Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Share Price?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you own shares in Apollo Endosurgery, Inc. (NASDAQ:APEN) thenRead More...
- Business Wire•4 days ago
Apollo Endosurgery Announces Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the publication of Outcomes of Endoscopic Gastroplasty in 1,000 Consecutive Patients from a single center - King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal Endoscopy - https://doi.org/10.1016/j.gie.2018.12.012.
- Simply Wall St.•last month
Apollo Endosurgery, Inc. (NASDAQ:APEN) Investors Are Paying Above The Intrinsic Value
In this article I am going to calculate the intrinsic value of Apollo Endosurgery, Inc. (NASDAQ:APEN) by taking the expected future cash flows and discounting them to their present value. Read More...
- Simply Wall St.•2 months ago
What does Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Balance Sheet Tell Us About Its Future?
Apollo Endosurgery, Inc. (NASDAQ:APEN) is a small-cap stock with a market capitalization of US$77m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
- Business Wire•2 months ago
Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018. This transaction will allow Apollo to focus all its efforts on growing the clinical adoption of its Endo-bariatric product offerings, which consists of its OverStitch Endoscopic Suturing Systems and the Orbera Intragastric Balloon technologies.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•3 months ago
Apollo Endosurgery Announces First Commercial Shipment of the OverStitch™ Sx Endoscopic Suturing System
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the first commercial shipments of the OverStitch™ Sx Endoscopic Suturing System. Flexible endoscopic suturing using Apollo’s OverStitch™ Endoscopic Suturing System is now established as an important tool for both surgeons and gastroenterologists that enables a wide array of new endolumenally performed patient treatment options. The OverStitch Sx is designed for compatibility with single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm, and therefore provides more physicians with access to the benefits of full-thickness flexible endoscopic suturing regardless of their hospital’s selection of endoscopic capital equipment or endoscope manufacturer.
- Business Wire•3 months ago
Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Obesity Week 2018 Conference
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced its participation during Obesity Week 2018 taking place November 11-15, 2018 at The Music City Center in Nashville, Tennessee. During the conference, Obesity Week will host several hands-on workshops including sessions that feature ORBERA® and OverStitch™ technologies. In addition the Apollo Mobile Learning Center will be in Nashville to support a series of hands-on physician training sessions.
- Business Wire•3 months ago
Apollo Endosurgery, Inc. Reports Third Quarter 2018 Results
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
- Business Wire•4 months ago
Apollo Endosurgery, Inc. to Report Third Quarter Results on November 8, 2018
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2018 on Thursday, November 8, 2018, after the U.S.
- Business Wire•5 months ago
Apollo Endosurgery Announces Distribution Agreement with Slater Endoscopy for the Ensizor® Flexible Endoscopic Scissors
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that it has entered into an agreement with Slater Endoscopy, LLC to distribute the cold Ensizor® Flexible Endoscopic Scissors in the United States, Europe, and select other markets. The Ensizor Flexible Endoscopic Scissor is indicated to cut and dissect tissue and sutures during endoscopic procedures. The rigid armature provides unparalleled strength while the flexible blades ensure constant cutting contact providing physicians reliable and consistent cutting performance.
- Business Wire•5 months ago
Apollo Endosurgery Completes Enrollment for the ORBERA Post Approval Study
The ORBERA Post Approval Study is a multi-center, open-label, prospective study of the safety and efficacy of the ORBERA system within the US. The study was a requirement of the US FDA’s approval of ORBERA in August of 2015.
- Business Wire•5 months ago
Apollo Endosurgery and Istituto Clinico Humanitas in Milano, Italy Establish European Registry for Flexible Endoscopic Suturing Procedures in Gastrointestinal Applications
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today an agreement with Istitudo Clinico Humanitas to establish a multicenter, retrospective, data repository for gastrointestinal applications performed using Apollo’s OverStitch™ Endoscopic Suturing System. Professor Alessandro Repici, Director of the Digestive Endoscopy Unit of Istituto Clinico Humanitas, will serve as the Principal Investigator. Endoscopic suturing can be used to support a wide variety of therapeutic, gastrointestinal endoscopic procedures.
- Simply Wall St.•5 months ago
What Does Apollo Endosurgery Inc’s (NASDAQ:APEN) Ownership Structure Look Like?
If you want to know who really controls Apollo Endosurgery Inc (NASDAQ:APEN), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows,Read More...
- Business Wire•7 months ago
Apollo Endosurgery, Inc. Reports Second Quarter 2018 Results
OverStitch™ Product Sales Increase 37% Year-Over-Year
- Business Wire•7 months ago
Apollo Endosurgery, Inc. to Report Second Quarter Results on August 8, 2018
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018, after the U.S.
- Business Wire•8 months ago
Apollo Endosurgery Receives Special 510(k) Clearance for OverStitch™ Sx Endoscopic Suturing System
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that it has received Special 510(k) clearance from the U.S. Food and Drug Administration for OverStitch™ Sx Endoscopic Suturing System. The OverStitch Sx System, a new, full-thickness flexible endoscopic suturing system, received initial 510(k) clearance in November 2017. The Special 510(k) addressed an accessory to the system that is intended to ease the attachment of the device to compatible endoscopes (single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm).
- Business Wire•8 months ago
Apollo Endosurgery, Inc. Announces Closing of Public Offering of Common Stock and Underwriter’s Full Exercise of Over-Allotment Option
Apollo Endosurgery, Inc. (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the closing of its previously announced underwritten public offering of 4,309,090 shares of its common stock, including 562,055 shares sold pursuant to the underwriter’s exercise in full of its option to purchase additional shares to cover over-allotments. Gross proceeds from the offering at a public offering price of $5.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $23.7 million. All of the common stock was offered and sold by Apollo.
- Benzinga•8 months ago
Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO ) Array Biopharma Inc (NASDAQ: ...
- Business Wire•8 months ago
Apollo Endosurgery, Inc. Announces Pricing of $20.6 Million Public Offering of Common Stock
Apollo Endosurgery, Inc. (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the pricing of an underwritten public offering of 3,747,035 shares of its common stock at a public offering price of $5.50 per share for gross proceeds of approximately $20.6 million. All of the common stock is being offered by Apollo. In addition, Apollo has granted the underwriter a 45-day option to purchase up to an additional 562,055 shares of common stock.
- Business Wire•8 months ago
Apollo Endosurgery, Inc. Announces Commencement of Public Offering of Common Stock
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriter a 45-day option to purchase additional shares of common stock.
- Business Wire•9 months ago
Apollo Endosurgery Announces Presentation of Mayo Clinic’s Clinical Study of ORBERA® Intragastric Balloon in Patients with Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week® 2018 (DDW)
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today’s presentation of results from Mayo Clinic’s prospective open-label study of the ORBERA® Intragastric Balloon in patients with Nonalcoholic Steatohepatitis (“NASH”) at Digestive Disease Week 2018. The FDA-approved study demonstrated the significant benefits of weight loss with the ORBERA Intragastric Balloon in patients with NASH and nonalcoholic fatty liver disease (NAFLD).
- Business Wire•9 months ago
Apollo Endosurgery Announces Presentation of Mortality and Inpatient Costs of Revisional Bariatric Surgery
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the presentation of the study results “Mortality and Inpatient Costs of Revisional Bariatric Surgery: A Nationwide Analysis” at Digestive and Disease Week in Washington, DC.
